arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Ultragenyx Pharmaceutical Inc.

RARE
$14.90 ▼ -0.70 (-4.46%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
56 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

Ultragenyx Pharmaceutical Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.5B
Dividend Yield
Revenue Growth 28.5%
Op. Margin -35.0%
ROIC 26.1%
FCF / Share $-0.96
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

56-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$214.00M
↑ +28.5%
Net Income Profit after all expenses
$-92.00M
↑ +20.0%
Operating Margin Operating profit as % of sales
-35.0%
↑ +71.8% 3th
FCF / Share Free cash flow per share
$-0.96
↑ +51.1%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
3
Cash Quality
55

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 15 years · 56 quarters